Finerenone (BAY94-8862)
Sponsors
Bayer
Conditions
Chronic Heart FailureChronic Kidney DiseaseDiabetic Kidney DiseaseDiabetic NephropathiesDiabetic NephropathyDiabetic RetinopathyHeart FailureNon-diabetic Chronic Kidney Disease
Phase 1
A Study to Learn How Finerenone (BAY94-8862) Moves Into, Through and Out of the Body, How it Affects the Body, and How Safe it is in Adult Participants With Different Degrees of Reduced Liver Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
CompletedNCT04881994
Start: 2014-03-25End: 2014-12-08Updated: 2021-07-16
A Study to Learn How BAY94-8862 Moves Into, Through and Out of the Body, How Safe it is and How it Affects the Body in Adult Participants With Reduced Kidney Function and in Healthy Participants With Similar Age, Weight and Gender Distribution
CompletedNCT04908436
Start: 2010-10-27End: 2012-01-27Updated: 2022-01-28
Phase 2
Phase IIb Safety and Efficacy Study of Different Oral Doses of BAY94-8862 in Subjects With Worsening Chronic Heart Failure and Left Ventricular Systolic Dysfunction and Either Type 2 Diabetes Mellitus With or Without Chronic Kidney Disease or Chronic Kidney Disease Alone
CompletedNCT01807221
Start: 2013-06-17End: 2014-12-09Updated: 2021-07-06
Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy
CompletedNCT01874431
Start: 2013-06-12End: 2014-08-07Updated: 2021-07-01
Phase 3
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
CompletedNCT02540993
Start: 2015-09-17End: 2020-04-14Updated: 2023-07-24
Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
CompletedNCT02545049
Start: 2015-09-17End: 2021-02-02Updated: 2022-04-15
Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%
CompletedNCT04435626
Start: 2020-09-14End: 2024-06-14Updated: 2025-08-26
A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease
CompletedNCT05047263
Start: 2021-09-21End: 2026-02-02Updated: 2026-02-13
Unknown Phase
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
CompletedNCT04477707
Start: 2020-07-23End: 2021-06-25Updated: 2022-06-29
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy, DR)
CompletedNCT04795726
Start: 2021-03-10End: 2021-06-30Updated: 2022-11-02
A Study to Learn More About How Safe Finerenone is and How Well it Works in Adults With Chronic Heart Failure in South Korea
RecruitingNCT07379840
Start: 2025-12-23End: 2027-09-30Target: 300Updated: 2026-02-03
Related Papers
73 more papers not shown